Blood Plasma Derivatives are also used to treat bleeding disorders. Some patients are unable to produce sufficient amounts of certain coagulation factors, which are proteins in the blood that help it clot. Factor VIII and Factor IX are used to treat Hemophilia A and Hemophilia B respectively, where those particular factors are deficient or defective. Recombinant versions can now be produced but plasma-derived concentrates remain an important treatment option. Factor VII is also derived from plasma and used in the treatment of rare bleeding disorders. Prothrombin complex concentrates containing Factors II, VII, IX and X are prescribed when there are deficiencies in multiple coagulation factors. Careful monitoring and dosage adjustments are required when using these plasma derivatives to successfully control and prevent bleeding episodes. (https://www.coherentmarketinsights.com/market-insight/blood-plasma-derivatives-market-5932)

Get more insights: Blood Plasma Derivatives (https://www.newswirestats.com/blood-plasma-derivatives-market-forecast-outlook-trend-2023-2030/)